Related Experiment Video
Updated: Apr 29, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Impairments of hepatic gluconeogenesis and ketogenesis in PPARα-deficient neonatal mice
David G Cotter1, Baris Ercal2, D André d'Avignon3
1Department of Medicine, Center for Cardiovascular Research, and Departments of Pediatrics.
Insights
Peroxisome proliferator activated receptor-α (PPARα) is crucial for neonatal adaptation to birth. PPARα deficiency impairs glycerol-to-glucose conversion and ketogenesis, leading to metabolic challenges in newborn mice.
Area of Science:
- Biochemistry
- Metabolic Regulation
- Neonatal Physiology
Background:
- Peroxisome proliferator activated receptor-α (PPARα) regulates hepatic metabolism and fasting responses.
- Nutrient supply drastically changes at birth, shifting from transplacental carbohydrates to a high-fat milk diet.
Purpose of the Study:
- To investigate the role of PPARα in hepatic metabolic adaptations during the neonatal period.
- To understand the impact of PPARα deficiency on glucose and fatty acid metabolism in newborn mice.
Main Methods:
- Utilized PPARα-knockout (KO) neonatal mice.
- Performed quantitative metabolic fate mapping using [(13)C]octanoate.
- Analyzed hepatic gene and protein expression of key metabolic enzymes (HMGCS2, BDH1).
- Measured blood acylcarnitine profiles and hepatic lipid concentrations.
Main Results:
- PPARα-KO neonates exhibited relative hypoglycemia due to impaired glycerol gluconeogenesis.
- Despite normal fatty acid oxidation, ketogenesis was reduced by 50% in PPARα-KO neonates.
- Decreased ketogenesis correlated with reduced HMGCS2 and BDH1 expression.
- Hepatic triglyceride and free fatty acid levels were significantly elevated in PPARα-KO neonates.
- Octanoate-derived carbon uniquely labeled glucose in PPARα-KO livers.
Conclusions:
- PPARα plays a critical role in neonatal hepatic metabolic adaptation, particularly in glycerol gluconeogenesis and ketogenesis.
- PPARα deficiency leads to impaired fatty acid disposal and altered glucose metabolism in newborns.
- These findings highlight a primary defect in gluconeogenesis and the importance of PPARα-dependent ketogenesis for neonatal metabolic homeostasis.
Abstract:
Peroxisome proliferator activated receptor-α (PPARα) is a master transcriptional regulator of hepatic metabolism and mediates the adaptive response to fasting. Here, we demonstrate the roles for PPARα in hepatic metabolic adaptations to birth. Like fasting, nutrient supply is abruptly altered at birth when a transplacental source of carbohydrates is replaced by a high-fat, low-carbohydrate milk diet. PPARα-knockout (KO) neonatal mice exhibit relative hypoglycemia due to impaired conversion of glycerol to glucose. Although hepatic expression of fatty acyl-CoA dehydrogenases is imparied in PPARα neonates, these animals exhibit normal blood acylcarnitine profiles. Furthermore, quantitative metabolic fate mapping of the medium-chain fatty acid [(13)C]octanoate in neonatal mouse livers revealed normal contribution of this fatty acid to the hepatic TCA cycle. Interestingly, octanoate-derived carbon labeled glucose uniquely in livers of PPARα-KO neonates. Relative hypoketonemia in newborn PPARα-KO animals could be mechanistically linked to a 50% decrease in de novo hepatic ketogenesis from labeled octanoate. Decreased ketogenesis was associated with diminished mRNA and protein abundance of the fate-committing ketogenic enzyme mitochondrial 3-hydroxymethylglutaryl-CoA synthase (HMGCS2) and decreased protein abundance of the ketogenic enzyme β-hydroxybutyrate dehydrogenase 1 (BDH1). Finally, hepatic triglyceride and free fatty acid concentrations were increased 6.9- and 2.7-fold, respectively, in suckling PPARα-KO neonates. Together, these findings indicate a primary defect of gluconeogenesis from glycerol and an important role for PPARα-dependent ketogenesis in the disposal of hepatic fatty acids during the neonatal period.
Related Concept Videos
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism

